404827-75-4

Basic information

• Product Name: 6-FLUORO-1H-INDAZOL-3-YLAMINE
• Synonyms: 6-FLUORO-1H-INDAZOL-3-YLAMINE;1H-Indazol-3-amine,6-fluoro-(9CI);6-fluoro-1H-indazol-3-aMine
• CAS NO: 404827-75-4
• Molecular Formula: C₇H₆FN₃
• Molecular Weight: 151.14
• Product Categories: HALIDE
• Mol File: 404827-75-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 379.288 °C at 760 mmHg
• Flash Point: 183.187 °C
• Appearance: /
• Density: 1.488 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 6-FLUORO-1H-INDAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-1H-INDAZOL-3-YLAMINE(404827-75-4)
• EPA Substance Registry System: 6-FLUORO-1H-INDAZOL-3-YLAMINE(404827-75-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 404827-75-4(Hazardous Substances Data)

Usage

General Description

6-FLUORO-1H-INDAZOL-3-YLAMINE, also known as 6-fluoro-1H-indazole-3-ylamine, is a chemical compound with the molecular formula C7H6FN3. It is a yellow solid that is commonly used in the pharmaceutical industry as a building block for the synthesis of various drug candidates. 6-FLUORO-1H-INDAZOL-3-YLAMINE is known to possess both anti-inflammatory and anti-cancer properties, making it a valuable component in the development of potential therapeutic agents. Additionally, its unique structure and properties make it a key target for research and development in the fields of medicinal and organic chemistry.

Upstream product

• 1219024-63-1 2-[2-(diphenylmethylene)hydrazino]-4-fluorobenzonitrile 
• 3939-09-1 2,4-difluorobenzonitrile 

Downstream Products

• 885522-07-6 6-fluoro-3-iodo-1H-indazole 

Relevant articles and documents

Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma

Growth, division, and development of healthy cells relies on efficient response to environmental survival cues. The conserved mitogen-activated protein kinase (MAPK) family of pathways interface extracellular stimuli to intracellular processes for this purpose. Within these pathways, the MEK family has been identified as a target of interest due to its clinical relevance. Particularly, MEK4 has drawn recent attention for its indications in pancreatic and prostate cancers. Here, we report two potent MEK4 inhibitors demonstrating significant reduction of phospho-JNK and antiproliferative properties against pancreatic cancer cell lines. Furthermore, molecular inhibition of MEK4 pathway activates the MEK1/2 pathway, with the combination of MEK1/2 and MEK4 inhibitors demonstrating synergistic effects against pancreatic cancer cells. Our inhibitors provided insight into the crosstalk between MAPK pathways and new tools for elucidating the roles of MEK4 in disease states, findings which will pave the way for better understanding of the MAPK pathways and development of additional probes.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.